Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADVIL CONGESTION RELIEF vs AFRINOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction
Afrinol is a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-1 adrenergic receptors in the vascular smooth muscle of nasal blood vessels, causing vasoconstriction and reducing nasal congestion. It also has weak alpha-2 agonist activity.
temporary relief of nasal congestion,sinus pressure,headache,fever,minor aches and pains associated with common cold or flu
Temporary relief of nasal congestion due to colds, hay fever, or other upper respiratory allergies.
1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.
Oral: 1 tablet (pseudoephedrine 120 mg, triprolidine 2.5 mg) every 12 hours; maximum 2 tablets per day.
Ibuprofen: 2-4 hours (short half-life requires frequent dosing). Pseudoephedrine: 5-8 hours (longer in alkaline urine). Context: Half-life prolonged in renal impairment.
9–11 hours in healthy adults; prolonged to 16–18 hours in hepatic cirrhosis and up to 20 hours in severe renal impairment. Clinical context: dosing interval typically 12 hours in normal renal function.
ibuprofen: primarily hepatic via CYP2C9; phenylephrine: primarily hepatic via monoamine oxidase (MAO) and sulfation
Primarily hepatic metabolism via oxidative deamination and glucuronidation; the major enzyme involved is monoamine oxidase (MAO).
Renal: ~90% as unchanged drug and metabolites (ibuprofen: <10% unchanged, pseudoephedrine: 43-96% unchanged). Biliary/fecal: minimal (<5%).
Renal (approximately 70–90% as unchanged drug and metabolites), with about 10% biliary/fecal elimination. Dose adjustment required in renal impairment (Cr Cl <30 m L/min).
Ibuprofen: >99% bound to albumin. Pseudoephedrine: 20-30% bound to albumin.
80–90% bound to serum albumin and alpha-1-acid glycoprotein.
Ibuprofen: 0.1-0.2 L/kg (low, reflects high protein binding). Pseudoephedrine: 2.6-3.5 L/kg (extensive tissue distribution).
4.0–5.0 L/kg. Indicates extensive tissue distribution, with concentrations exceeding plasma levels in lung, liver, kidney, and brain.
Oral: Ibuprofen ~80-100% (high), Pseudoephedrine ~100% (high).
Oral: 40–50% (first-pass metabolism). Intranasal: 70–80% (systemic absorption variable). Intravenous: 100%.
Avoid use if Cr Cl <30 m L/min. For Cr Cl 30-59 m L/min, use lowest effective dose and shortest duration.
Cr Cl 30-50 m L/min: prolong interval to every 18-24 hours; Cr Cl <30 m L/min: avoid use.
Avoid use in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), use with caution and at the lowest effective dose.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, consider dose reduction; Child-Pugh C: avoid use.
Not recommended in children under 12 years of age due to phenylephrine component. For children 12 years and older, same as adult dosing.
Children 6-12 years: 1/2 tablet (pseudoephedrine 60 mg, triprolidine 1.25 mg) every 12 hours; maximum 1 tablet per day. Children <6 years: not recommended.
Start at the low end of dosing range; avoid use in patients 65 years and older if possible due to increased risk of adverse effects; if necessary, use lowest effective dose for shortest duration.
Start with 1/2 tablet (pseudoephedrine 60 mg, triprolidine 1.25 mg) every 12 hours; monitor for CNS effects, anticholinergic side effects, and hypertension.
ibuprofen carries a black box warning for increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal, and for serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines
None.
cardiovascular risk,gastrointestinal risk,renal effects,avoid concomitant use of other NSAIDs,hypertension,hyperthyroidism,diabetes,heart disease,use with MAOIs may cause hypertensive crisis
Hypertension, cardiovascular disease, hyperthyroidism, diabetes mellitus, increased intraocular pressure, prostatic hyperplasia; use caution in elderly patients; do not exceed recommended dosage.
hypersensitivity to ibuprofen, phenylephrine, or any component,history of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs,perioperative pain in setting of coronary artery bypass graft (CABG) surgery,severe hypertension,severe coronary artery disease,use of MAOIs or within 14 days of stopping MAOIs
Hypersensitivity to any component; concurrent use or recent use (within 14 days) of MAO inhibitors; severe hypertension or coronary artery disease.
Avoid alcohol consumption due to increased risk of GI bleeding and liver damage. No specific food interactions; take with food or milk to reduce stomach upset. Caffeine may exacerbate pseudoephedrine's stimulant effects; limit caffeine intake.
Avoid excessive caffeine intake as it may increase stimulant effects. No significant food interactions known.
First trimester: Avoid due to potential increased risk of cardiac defects and gastroschisis from NSAIDs. Second trimester: Use with caution; ibuprofen may cause oligohydramnios and premature ductus arteriosus constriction. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. Phenylephrine: Limited human data; animal studies show fetal abnormalities at high doses; avoid in first trimester due to potential vascular disruption.
Afrinol (pseudoephedrine) is generally considered low risk during pregnancy. First trimester: Some studies suggest a possible association with gastroschisis, but data are inconsistent. Second and third trimesters: Avoid due to risk of uterine vasoconstriction and potential fetal hypoxia, especially near term. Overall, FDA Pregnancy Category C.
Ibuprofen: Excreted into breast milk in low amounts (M/P ratio ~0.07). Compatible with breastfeeding; minimal infant exposure. Phenylephrine: Not known if excreted in breast milk; M/P ratio unknown. Avoid due to potential for infant hypertension and irritability. Alternative decongestants preferred.
Pseudoephedrine is excreted into breast milk in small amounts (M/P ratio approximately 2.6–3.5). Use with caution as it can reduce milk production and may cause irritability in the infant. A single dose is likely safe, but chronic use is not recommended.
Pharmacokinetic changes in pregnancy: Increased volume of distribution and clearance for ibuprofen may require higher doses, but avoid due to fetal risks. No standard dose adjustment recommended; use lowest effective dose for shortest duration. Phenylephrine: No specific dosing adjustments in pregnancy; avoid use due to limited safety data.
No specific dose adjustments are established for pregnancy. However, due to increased plasma volume and renal clearance, the duration of action may be shorter. Use the lowest effective dose for the shortest duration, typically 60 mg every 4–6 hours (max 240 mg/day).
Advil Congestion Relief combines ibuprofen (NSAID) and pseudoephedrine (decongestant). Ibuprofen can cause nephrotoxicity; pseudoephedrine can elevate blood pressure and heart rate. Avoid in patients with uncontrolled hypertension, severe CAD, or MAOI use within 14 days. Use with caution in elderly due to increased risk of GI bleeding and CNS effects. Not recommended for children under 12 years.
AFRINOL contains oxymetazoline, an imidazoline sympathomimetic with alpha-adrenergic agonist activity. It causes vasoconstriction in nasal mucosa. Limit use to 3 days to avoid rhinitis medicamentosa. Avoid in patients with narrow-angle glaucoma, severe hypertension, or MAOI use. Onset is within minutes, duration up to 12 hours.
Do not take more than directed; do not use with other products containing ibuprofen or other NSAIDs (e.g., naproxen, aspirin) due to increased risk of stomach bleeding.,Avoid alcohol while taking this medication to reduce the risk of stomach irritation and bleeding.,Pseudoephedrine may cause insomnia, nervousness, or dizziness; take the last dose at least 4-6 hours before bedtime.,Stop use and consult a doctor if symptoms persist after 5 days (fever >3 days), if new symptoms appear, or if you experience signs of stomach bleeding (black/bloody stools, vomit with blood/coffee-grounds).,Do not use if you have heart disease, high blood pressure, thyroid disease, diabetes, glaucoma, or difficulty urinating due to an enlarged prostate unless directed by a doctor.
Do not use for more than 3 consecutive days to avoid rebound congestion.,Do not share the bottle with others to prevent infection.,Do not exceed recommended dosage; use only 2-3 sprays per nostril every 10-12 hours as directed.,Avoid using if you have high blood pressure, heart disease, or glaucoma without consulting a doctor.,Consult a doctor if symptoms persist beyond 3 days or if you experience severe side effects like headache, rapid heartbeat, or dizziness.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADVIL CONGESTION RELIEF vs AFRINOL, answered by our medical review team.
ADVIL CONGESTION RELIEF is a NSAID/Decongestant Combination that works by ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction. AFRINOL is a Decongestant that works by Afrinol is a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-1 adrenergic receptors in the vascular smooth muscle of nasal blood vessels, causing vasoconstriction and reducing nasal congestion. It also has weak alpha-2 agonist activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADVIL CONGESTION RELIEF and AFRINOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADVIL CONGESTION RELIEF is: 1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.. The standard adult dose of AFRINOL is: Oral: 1 tablet (pseudoephedrine 120 mg, triprolidine 2.5 mg) every 12 hours; maximum 2 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADVIL CONGESTION RELIEF and AFRINOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADVIL CONGESTION RELIEF is classified as Category C. First trimester: Avoid due to potential increased risk of cardiac defects and gastroschisis from NSAIDs. Second trimester: Use with caution; ibuprofen may cause oligohydramnios and. AFRINOL is classified as Category C. Afrinol (pseudoephedrine) is generally considered low risk during pregnancy. First trimester: Some studies suggest a possible association with gastroschisis, but data are inconsist. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.